| Pyelonephritis
Recarbrio vs Vabomere
Side-by-side clinical, coverage, and cost comparison for pyelonephritis.Deep comparison between: Recarbrio vs Vabomere with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVabomere has a higher rate of injection site reactions vs Recarbrio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vabomere but not Recarbrio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Recarbrio
Vabomere
At A Glance
IV infusion
Every 6 hours
Carbapenem + beta-lactamase inhibitor
IV infusion
Every 8 hours
Carbapenem + beta-lactamase inhibitor
Indications
- Hospital acquired bacterial pneumonia
- VABP
- Complicated urinary tract infection
- Pyelonephritis
- Complicated intra-abdominal infection
- Complicated urinary tract infection
- Pyelonephritis
Dosing
Hospital acquired bacterial pneumonia, VABP, Complicated urinary tract infection, Pyelonephritis, Complicated intra-abdominal infection Adults with CLcr >=90 mL/min: 1.25 g (imipenem 500 mg/cilastatin 500 mg/relebactam 250 mg) IV infusion over 30 minutes every 6 hours for 4-14 days; dose reduction required for CLcr <90 mL/min; pediatric patients (>=2 kg): weight- and age-based dosing of 37.5 mg/kg every 6-8 hours IV.
Complicated urinary tract infection, Pyelonephritis 4 grams (meropenem 2 grams and vaborbactam 2 grams) IV infusion over 3 hours every 8 hours for up to 14 days in patients with eGFR >=50 mL/min/1.73m2; dose adjustment required for eGFR <50 mL/min/1.73m2 (2 grams every 8 hours for eGFR 30-49, 2 grams every 12 hours for eGFR 15-29, 1 gram every 12 hours for eGFR <15).
Contraindications
- Severe hypersensitivity (e.g., anaphylaxis) to any component of RECARBRIO
- Known hypersensitivity to any component of VABOMERE (meropenem and vaborbactam) or to other drugs in the same class
- Demonstrated anaphylactic reactions to beta-lactam antibacterial drugs
Adverse Reactions
Most common (>=4%) Anemia, diarrhea, AST increased, ALT increased, hypokalemia, hyponatremia, constipation, pyrexia, rash
Serious Hypersensitivity reactions, seizures and other CNS adverse reactions, Clostridioides difficile-associated diarrhea
Most common (>=3%) Headache, phlebitis/infusion site reactions, diarrhea
Serious Hypersensitivity reactions, seizures, rhabdomyolysis, Clostridioides difficile-associated diarrhea, breakthrough seizures (valproic acid interaction), thrombocytopenia, neuromotor impairment
Postmarketing Rhabdomyolysis, drug-induced liver injury (DILI) including hepatitis and liver failure
Pharmacology
RECARBRIO combines imipenem (a carbapenem that inhibits bacterial cell wall synthesis by binding PBP 2 and PBP 1B), cilastatin (a renal dehydropeptidase inhibitor that prevents renal metabolism of imipenem), and relebactam (a diazabicyclooctane beta-lactamase inhibitor that protects imipenem from degradation by serine beta-lactamases including KPC, AmpC-type PDC, SHV, TEM, and CTX-M enzymes).
Meropenem is a penem antibacterial that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins in gram-positive and gram-negative bacteria; vaborbactam is a cyclic boronic acid, non-suicidal beta-lactamase inhibitor that protects meropenem from degradation by serine beta-lactamases, including Klebsiella pneumoniae carbapenemase (KPC), without intrinsic antibacterial activity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Recarbrio
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (6/12) · Qty limit (0/12)
Vabomere
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Recarbrio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Vabomere
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Recarbrio
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Vabomere
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Recarbrio.
No savings programs available for Vabomere.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RecarbrioView full Recarbrio profile
VabomereView full Vabomere profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.